Targeted Cancer Therapy and Its Ophthalmic Side Effects: A Review

Shruthi Harish Bindiganavile; Nita Bhat; Andrew G. Lee; Dan S. Gombos; Nagham Al-Zubidi

doi:10.36401/JIPO-20-21

Journal of Immunotherapy and Precision Oncology (Feb 2021)

Targeted Cancer Therapy and Its Ophthalmic Side Effects: A Review

Shruthi Harish Bindiganavile,
Nita Bhat,
Andrew G. Lee,
Dan S. Gombos,
Nagham Al-Zubidi

Affiliations

Shruthi Harish Bindiganavile: 1 Department of Ophthalmology, Blanton Eye Institute, Houston Methodist Hospital, Houston, TX, USA
Nita Bhat: 1 Department of Ophthalmology, Blanton Eye Institute, Houston Methodist Hospital, Houston, TX, USA
Andrew G. Lee: 1 Department of Ophthalmology, Blanton Eye Institute, Houston Methodist Hospital, Houston, TX, USA
Dan S. Gombos: 4 Department of Ophthalmology, University of Texas Medical Branch, Galveston, TX, USA
Nagham Al-Zubidi: 1 Department of Ophthalmology, Blanton Eye Institute, Houston Methodist Hospital, Houston, TX, USA

DOI: https://doi.org/10.36401/JIPO-20-21

Abstract

Read online

Targeted cancer therapy agents are the latest development in cancer therapeutics. Although the spectrum of their use continues to expand, ocular side effects are frequently encountered with the use of cancer therapeutics. This review describes the ocular side effects of targeted cancer therapy agents.

Published in Journal of Immunotherapy and Precision Oncology

ISSN: 2666-2345 (Print); 2590-017X (Online)
Publisher: Innovative Healthcare Institute
Country of publisher: United States
LCC subjects: Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens; Medicine: Internal medicine: Specialties of internal medicine: Immunologic diseases. Allergy
Website: https://meridian.allenpress.com/innovationsjournals-JIPO

About the journal

Abstract

Keywords